GenVec (GNVC) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GenVec (GNVC) FY14 Results Flat with Views; Hearing Loss Phase I Update Encouraging - Roth Capital
March 24, 2015 2:12 PM EDTRoth Capital affirms GenVec (Nasdaq: GNVC) at Buy with a price target of $8 following FY14 results.
Analyst Joseph Pantginis noted that GenVec posted FY14 loss of $0.16 per share, which was in-line with the firm's estimate. GenVec also ended FY14 with $14.7 million in cash and that should fund operations through 2017. As... More
GenVec (GNVC), TheraBiologics Enter Collaboration for Cancer Therapeutics Technology Development
March 23, 2015 7:04 AM EDTGenVec (NASDAQ: GNVC) announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.
In exchange for an economic participation in the products being developed under the collaboration, GenVec will contribute technology, know-how, vector construction, and technical and regulatory support to the program. TheraBiologics will be... More
